MktsMarkets

Dermata Therapeutics, Inc.
NASDAQ: DRMAKey statistics
DRMA News
Stories mentioning DRMA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 384.00 | 527.00 | 504.00 | 618.00 | 1,281 | 2,193 | 2,401 | 2,009 |
| Sales General & Admin | 1,543 | 1,256 | 1,059 | 824.00 | ||||
| Total Operating Expenses | 1,926 | 1,900 | 1,761 | 1,773 | 2,340 | 3,199 | 3,226 | 2,884 |
| Operating Income (Loss) | (1,926) | (1,900) | (1,761) | (1,773) | (2,340) | (3,199) | (3,226) | (2,884) |
| Interest Income | 79.00 | 38.00 | 69.00 | 72.00 | 36.00 | 50.00 | 52.00 | 55.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (1,848) | (1,862) | (1,692) | (1,701) | (2,304) | (3,151) | (3,173) | (2,829) |
| Earnings Per Share (Basic) | (0.48) | (2.01) | (1.65) | (1.66) | (4.47) | (20.59) | (20.41) | (41.82) |
| Earnings Per Share (Diluted) | (0.48) | (2.01) | (1.65) | (1.66) | (4.47) | (20.59) | (20.41) | (41.82) |
| Weighted Average Shares Outstanding (Basic) | 3,859 | 926.00 | 1,026 | 1,027 | 515.00 | 153.00 | 155.00 | 68.00 |
| Weighted Average Shares Outstanding (Diluted) | 3,859 | 926.00 | 1,026 | 1,027 | 515.00 | 153.00 | 155.00 | 68.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About DRMA
Dermata Therapeutics, Inc. (NASDAQ: DRMA) is a stock listed on the Nasdaq Stock Market under the ticker symbol DRMA. It last traded at $0.6600 (Nov 12, 2026, 4:00 PM ET), down 7.6% on the day. That gives Dermata Therapeutics a market capitalisation of $3.5M.
Over the past 52 weeks DRMA has traded between $0.6000 and $4.66.
For the quarter ended Mar 31, 2026 it reported a net loss of $1.8M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$1.8M |
| Dec 31, 2025 | — | -$1.9M |
| Sep 30, 2025 | — | -$1.7M |
| Jun 30, 2025 | — | -$1.7M |
From Dermata Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…